Molecular Profiling Enhances Treatment Precision for Endometrial Cancer Patients

Recent findings from a significant international study indicate that molecular profiling can effectively minimize radiation therapy for women diagnosed with endometrial cancer, particularly those classified with high-intermediate risk. This evidence was presented at the annual congress of the European Society for Radiotherapy and Oncology (ESTRO), emphasizing the potential for more personalized cancer treatment.

Endometrial cancer, the most prevalent gynecological cancer in developed nations, predominantly affects postmenopausal women. While early-stage diagnoses typically lead to favorable treatment outcomes, the standard care involving adjuvant radiotherapy--especially vaginal brachytherapy--may not be necessary for all patients. This could lead to unnecessary exposure to side effects for some, while a small subgroup may not receive adequate treatment.

The PORTEC-4a trial, which included 592 women from eight European countries, aimed to address this issue by employing molecular profiling to tailor treatment based on the genetic characteristics of each tumor. The study's results revealed that nearly half of the participants could safely forgo radiation therapy without compromising cancer control.

Key findings from the trial included:

• Targeted Treatment: Molecular profiling allows for customized radiotherapy decisions, aligning treatment with individual tumor characteristics.
• Reduced Overtreatment: Approximately 46% of trial participants in the molecular profiling group successfully avoided radiation, demonstrating a significant reduction in unnecessary treatments.
• Improved Outcomes for High-Risk Patients: Those with unfavorable tumor profiles were directed to receive more intensive radiation therapy, which enhanced locoregional control and resulted in a lower recurrence rate of 8.4%, compared to 30.5% in those receiving standard treatment.

Dr. Anne Sophie V.M. van den Heerik, the lead investigator, highlighted that the use of molecular profiling not only optimizes treatment but also ensures that patients who require more aggressive therapy receive it effectively. This approach signifies a major advancement towards personalized and less invasive cancer treatment options.

Prof. Matthias Guckenberger, President of ESTRO, termed the PORTEC-4a trial a transformative step in precision oncology. He noted that the research underscores the importance of identifying patients who would benefit most from radiotherapy, thereby maximizing treatment efficacy while enhancing the quality of life for many women globally.

As the incidence of endometrial cancer continues to rise, these findings pave the way for a more tailored approach in managing the disease, focusing on minimizing invasive treatments while ensuring the best possible outcomes based on individual risk profiles and tumor biology.